Welcome to Next Generation Pain Treatment

Based on a novel product class, SantoSolve is developing a new generation of analgesic agents to create a safer and better future for pain patients.

Latest news:
Friday, 18 January 2008 - SantoSolve, a biopharmaceutical company focused on developing novel pain therapies today announced positive results from its Phase II study of 2PX, the company’s topical analgesic, in patients with osteoarthritis (OA). Read more...